Vaccine News and Research

Latest Vaccine News and Research

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City.

1 Dec 2009

Research shows many factors can impact people's decisions on getting vaccinated

Just because a vaccine is available doesn't mean people will choose to be inoculated, according to new UofT research published amid widespread public confusion around the merit of H1N1 flu shots.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

30 Nov 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

27 Nov 2009

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

The Board of Directors of Tripep AB (publhas on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue.

27 Nov 2009

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.

27 Nov 2009

B cells and their antibodies defend against microbes and control commensal microflora

Microbes populated the earth long before any eukariotic cell. Therefore, in order to survive, mono and multi-cellular organisms had to develop mechanisms of adaptation, cohabitation and defense against bacteria, fungi and viruses. One of these mechanisms is mediated by immunoglobulins in the serum and at mucosal surfaces.

27 Nov 2009

Melvin R. Kaplan to be honored for his lifetime devotion to the care of patients

Melvin R. Kaplan, MD, FACP, a former Board Chair and one of the founders of the research institute that became Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), will be honored by the American College of Physicians for his lifetime devotion to the care of patients.

26 Nov 2009

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. S-kaly from the Universit- de Montr-al.

26 Nov 2009

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease.

26 Nov 2009

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

In honor of World AIDS Day, The AIDS Institute (TAI), one of the nation's leading advocacy organizations for support of people with HIV/AIDS and their providers, joined Nobel Laureate Dr. Francoise Barre-Sinoussi, in calling for government leaders, patient advocates and the research community to expand therapeutic HIV vaccine research.

26 Nov 2009

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.

25 Nov 2009

WHO investigates cases of H1N1 drug resistance in U.S., Britain

The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.

25 Nov 2009

Unilife Medical Solutions files a patent application for its Unifill Select ready-to-fill syringe

Unilife Medical Solutions Limited today announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.

25 Nov 2009

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

25 Nov 2009

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February 21, 2010.

25 Nov 2009

Synexus recruits patients to study paediatric vaccine against rotavirus

UK-based Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials, recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus.

From AES - Accelerated Enrollment Solutions 25 Nov 2009

Vaccine News and Research

Latest Vaccine News and Research

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

Research shows many factors can impact people's decisions on getting vaccinated

Clinical trials of personalised vaccines to fight glioblastomas

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

B cells and their antibodies defend against microbes and control commensal microflora

Melvin R. Kaplan to be honored for his lifetime devotion to the care of patients

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

WHO investigates cases of H1N1 drug resistance in U.S., Britain

Unilife Medical Solutions files a patent application for its Unifill Select ready-to-fill syringe

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Novartis to terminate its research collaboration agreement with Idera Pharmaceuticals

Synexus recruits patients to study paediatric vaccine against rotavirus

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in